

## ASX ANNOUNCEMENT

### Receipt of Shareholder statement

23 OCTOBER 2024

Melbourne, Australia – In accordance with ASX Listing Rule 3.17A.1, Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**) advises that it has received a statement pursuant to section 249L of the *Corporations Act 2001* (Cth) (**Statement**) from Elizabeth Sarah Jansen as trustee for the Stanford Investment Trust in response to the Company's Notice of 2024 Annual General Meeting that was released by Vitura earlier today, Wednesday, 23 October 2024. A copy of the Statement is attached.

\*\* ENDS \*\*

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





## About Vitura Health Limited (ASX: VIT)

[www.vitura.com.au](http://www.vitura.com.au)

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)  
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- [www.canview.com.au](http://www.canview.com.au)  
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- [www.doctorsondemand.com.au](http://www.doctorsondemand.com.au)  
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- [www.cortexa.com.au](http://www.cortexa.com.au)  
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- [www.cdaclinics.com.au](http://www.cdaclinics.com.au)  
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- [www.cannadoc.com.au](http://www.cannadoc.com.au)  
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.



### **Authorised by**

Robert Iervasi, Chair and Non-Executive Director

### **Contact**

#### **Vitura Health Limited**

Robert Iervasi

Chair

1300 799 491

[info@vitura.com.au](mailto:info@vitura.com.au)

#### **Media enquiries**

Rebecca Harrison

The Civic Partnership

+61 408 529 751

[rebecca.harrison@civicpartners.com.au](mailto:rebecca.harrison@civicpartners.com.au)

### **Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

For personal use only

23/10/2024

**Trustee for the Stanford Investment Trust Statement to the Vitura Health Limited Shareholders re: Resolutions at Vitura Health Limited 2024 AGM**

Kind regards,



**ES Jansen**

Attached from next page

---

For personal use only

---

## VOTE TO **PROTECT** VITURA SHAREHOLDERS' INTERESTS

**Dear Vitura Health Shareholders,**

As a major shareholder, I am pleased to be communicating with the shareholders of Vitura.

Last year we offered 3 virtuous, insightful, and valuable candidates for appointment to the Board, together with shareholder statements for distribution that included alerts to fellow shareholders to avoid 'resolutions of dilution'. These were opposed by the then 2023 Vitura Board of Directors in an unprecedented manner. This is the same Board that had issue with my husband and founder Dr Ben Jansen on the Board; who was advocating for the clinics, the research & development program, our staff, our patients, our culture, our mutual shareholder interests, keeping to CDA's successful founding principles and most importantly investing into Vitura rather than executive bonuses.

Since that time, the company, the Board of Directors and the stock price performance can speak for itself; and we applaud the departure of Rodney Cocks. Executive remuneration increasing whilst shareholder returns were decreasing were one of the performance markers of his tenure.

We are comforted that all the 2023 Board members have decided to exit to enable the company to grow and flourish into the future.

We welcome Rob Iervasi as new Chairman of the Board to reset the Board and company.

Yours Virtuously,



**Elizabeth Sarah Jansen**

Trustee of Stanford  
Investment Trust, Fellow  
Shareholder, and Former  
Chief Research Officer<sup>^</sup>

*PHDcan, MSc, BSc, BPHHealth*

*<sup>^</sup>CAU (VIT named changed  
from CAU after CDA Health  
'merger')*